London open: FTSE tracks gains in US
26th Aug 2014 09:26
- Jackson hole comments drive gains - S&P 500 surpasses 2,000 - Bunzl, WPP gain techMARK 2,828.25 +0.18% FTSE 100 6,800.64 +0.37% FTSE 250 15,924.69 +0.27% London's blue chips delivered decent gains on Tuesday morning as they followed in the steps of US stocks, which on Monday night were driven hi
Read moreFTSE 100 movers: Miners slide as Astra gains on bid speculation
21st Aug 2014 18:01
Mining stocks led the downside after metals consumer China disappointed with its manufacturing data and metal prices fell. Fresnillo, Randgold Resources, Anglo American, Rio Tinto and BHP Billiton all fell into the red. BHP was still under pressure in the aftermath of Tuesday's underwhelming plans
Read moreSector movers: Astrazeneca boosts pharma stocks on Pfizer return hopes
21st Aug 2014 17:48
Astrazenca was leading the pharmaceuticals sector higher on Thursday on the back of speculation that US drug giant Pfizer could return with a fresh offer in the coming days. The reports lifted others in the sector higher in afternoon trading with peers such as Glaxosmithkline, Hikma and BTG making
Read moreLondon close: Astrazeneca leads FTSE higher on bid speculation
21st Aug 2014 17:42
- Healthcare stocks lift FTSE - German PMI data drives sentiment - Investors look ahead to Draghi speech - UK retail sales disappoint techMARK 2,819.77 +0.82% FTSE 100 6,777.66 +0.33% FTSE 250 15,838.57 +0.57% London's blue chips ended Thursday's session on a positive note, led by Astrazeneca. Inc
Read moreLondon midday: UK stocks advance as investors shrug off weak data
21st Aug 2014 12:01
- Mining stocks fall as Chinese data weakens - Eurozone PMIs and UK retail sales disappoint - US data, Jackson Hole ahead techMARK 2,810.76 +0.50% FTSE 100 6,772.04 +0.25% FTSE 250 15,797.15 +0.31% Falls in the heavyweight mining sector weren't enough to stop the FTSE 100 from advancing on Thursda
Read moreAstraZeneca relief as US DoJ closes investigation into Brilinta
19th Aug 2014 08:37
A US Department of Justice investigation into clinical trials carried out by AstraZeneca has been closed with no further action to be taken. Astra underwent investigation into its 'Plato' trials of heart drug Brilinta in October 2013, with media speculation that this was due to inaccurate results b
Read moreAstrazeneca progresses with treatment for antibioitc-resistant infections
19th Aug 2014 08:35
Astrazeneca has reported progress in studies of its antibiotic drug that could be used in hospitalised adult patients with complicated intra-abdominal infections. The studies into ceftazidime-avibactam (CAZ-AVI), known as reclaim-1 and reclaim-2, are examining whether the combination of a new gener
Read moreAstraZeneca starts phase III of asthma drug Tralokinaums
14th Aug 2014 08:43
Pharmaceutical giant AstraZeneca has started phase III of its asthma control medicine, Tralokinaums, in an effort to strengthen its respiratory portfolio. Phase three of the programme will see the group assess the safety of its newly designed treatment, made by its research division MedImmune. Tr
Read moreFTSE 100 movers: Admiral and Glencore shares fall after H1 results
13th Aug 2014 14:49
Car insurance group Admiral was a heavy faller on Wednesday after the group said turnover in the first half was down 5% at £1.04bn as a 9% rise in customers was outweighed by a fall in premiums over last year. The company said that while UK premiums are no longer falling a return to growth remains e
Read moreLondon midday: Stocks advance as rate-hike speculation eases
13th Aug 2014 12:08
- BoE strikes dovish tone as wages fall - Ukraine crisis, Asian data in focus - Ex-dividend stocks limit upside - Banking stocks lead upside techMARK 2,736.01 +0.28% FTSE 100 6,661.68 +0.44% FTSE 250 15,528.53 +0.41% An overall dovish tone to the Bank of England's (BoE) Inflation Report gave UK st
Read moreAstrazeneca reports positive results from gout treatment tests
13th Aug 2014 09:07
Drug group Astrazeneca said it had achieved positive results in trials of a gout treatment. Astrazeneca said pivotal phase three clinical trials of lesinurad, a selective uric acid re-absorption inhibitor used to treat patients with symptomatic gout, had hit primary targets. The group said, howeve
Read moreLondon open: Stocks flat on rate speculation ahead of Inflation Report
13th Aug 2014 09:04
- Inflation Report, rate speculation keeps markets cautious - Ukraine crisis in focus as Russian convoy heads to border - Chinese data disappoints, Japanese GDP sinks - Ex-dividend stocks fall techMARK 2,725.51 -0.10% FTSE 100 6,630.77 -0.02% FTSE 250 15,403.28 -0.40% Weak economic data from Asia,
Read moreFTSE 100 movers: Pharma stocks drop as regulation looks to derail M&A
6th Aug 2014 14:26
Shire, the pharmaceutical group which has agreed to a £32bn takeover by Abbvie, saw its shares decline sharply on Wednesday on concerns that stricter rules on so-called 'tax inversion' in the States could scupper the deal. Sector peer Astrazeneca, which had recently been the target of a failed £69b
Read moreShire shares slump as US looks to deter tax inversion deals
6th Aug 2014 14:14
Shire, the pharmaceutical group that has agreed to a £32bn takeover by Abbvie, saw its share price sink sharply on Wednesday on concerns that stricter rules on so-called 'tax inversion' in the States could scupper the deal. The US Treasury Department said it was looking at ways to deter American co
Read moreSector movers: Shire and AZN lead pharma stocks lower on M&A risk
6th Aug 2014 14:13
The pharmaceutical sector dropped on Wednesday on the back of fears about risks to mergers and acquisitions (M&A) activity, with Shire sinking sharply. Concerns that stricter rules on so-called 'tax inversion' in the US could scupper Abbvie's £32bn takeover of London-listed Shire dented the latter'
Read more